Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

But the results add to evidence from animal studies and reports that people are finding drugs like Ozempic and Wegovy helpful ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

When you buy through links on our articles, Future and its syndication partners may earn a commission.

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.